[
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of December 15",
    "summary": "Stay updated on dividend activity for top companies, including changes in dividends and upcoming ex-dividend and pay dates.",
    "url": "https://finnhub.io/api/news?id=33fc43392efd9cfd584d56169da5b7754635c9c7d87d7a9f028ac564d6f5e124",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734126012,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of December 15",
      "id": 131975776,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Stay updated on dividend activity for top companies, including changes in dividends and upcoming ex-dividend and pay dates.",
      "url": "https://finnhub.io/api/news?id=33fc43392efd9cfd584d56169da5b7754635c9c7d87d7a9f028ac564d6f5e124"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Raises Quarterly Dividend to $0.43, Offering 6.66% Yield",
    "summary": "Pfizer Announces 345th Consecutive Dividend Payment with 6.66% Increase",
    "url": "https://finnhub.io/api/news?id=c7f98f82cfa8bade1ef9d4c2d3327112570eaa9e692b70459016301fcfda6aee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734110449,
      "headline": "Pfizer Raises Quarterly Dividend to $0.43, Offering 6.66% Yield",
      "id": 131974843,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/da95b7cbbb6f9163c79b51abb0059b08",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Announces 345th Consecutive Dividend Payment with 6.66% Increase",
      "url": "https://finnhub.io/api/news?id=c7f98f82cfa8bade1ef9d4c2d3327112570eaa9e692b70459016301fcfda6aee"
    }
  },
  {
    "ts": null,
    "headline": "Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report",
    "summary": "The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes. Gilead Sciences Inc's (NASDAQ:GILD) Biktarvy, Johnson & Johnson's (NYSE:JNJ) Darzalex, Novartis AG's (NYSE:NVS) Entresto, Exelixis Inc (NASDAQ:EXEL) Cabometyx, and Pfizer Inc's (NYSE:PFE) Xeljanz are among the five drugs flagged for unsupported price increases. These five drugs' unsupported net price increases produce",
    "url": "https://finnhub.io/api/news?id=d28d4693d9b26aba0c475cf9417d5765371c0188a847ccf03da3198915d64a0d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734110107,
      "headline": "Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report",
      "id": 131969673,
      "image": "https://media.zenfs.com/en/Benzinga/a1f6fcbf33264a5c95130e307843f218",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes. Gilead Sciences Inc's (NASDAQ:GILD) Biktarvy, Johnson & Johnson's (NYSE:JNJ) Darzalex, Novartis AG's (NYSE:NVS) Entresto, Exelixis Inc (NASDAQ:EXEL) Cabometyx, and Pfizer Inc's (NYSE:PFE) Xeljanz are among the five drugs flagged for unsupported price increases. These five drugs' unsupported net price increases produce",
      "url": "https://finnhub.io/api/news?id=d28d4693d9b26aba0c475cf9417d5765371c0188a847ccf03da3198915d64a0d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=b2d722fdb81eaeadf80692164e3e1dd17cc10781e4d43473d56d04b363179853",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734107940,
      "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "id": 132066919,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=b2d722fdb81eaeadf80692164e3e1dd17cc10781e4d43473d56d04b363179853"
    }
  },
  {
    "ts": null,
    "headline": "Genmab A/S: Circling Back On This Complicated Story",
    "summary": "Genmab A/S shares dropped 25% despite positive data and acquisition of ProfoundBio. Click for my updated look at GMAB stock prospects.",
    "url": "https://finnhub.io/api/news?id=0297f49b63cdcfda69bf3a1f6304240a305d8a14e60f2c6559ce19d0f6f6ee78",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734102652,
      "headline": "Genmab A/S: Circling Back On This Complicated Story",
      "id": 131971273,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Genmab A/S shares dropped 25% despite positive data and acquisition of ProfoundBio. Click for my updated look at GMAB stock prospects.",
      "url": "https://finnhub.io/api/news?id=0297f49b63cdcfda69bf3a1f6304240a305d8a14e60f2c6559ce19d0f6f6ee78"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer announces results from PATINA trial",
    "summary": "Pfizer (PFE) and Alliance Foundation Trials announced results from the Phase 3 PATINA trial demonstrating that the addition of Ibrance to current standard-of-care first-line maintenance therapy resulted in statistically significant and clinically meaningful improvement in progression-free survival, or PFS, by investigator assessment in patients with hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer. In the study, which is sponsored by AFT, medi",
    "url": "https://finnhub.io/api/news?id=6b3e844fca8c0fa45fef1bccbdb8f1ba8df0e9f4fa50e15d87d9cb49261d7208",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734096029,
      "headline": "Pfizer announces results from PATINA trial",
      "id": 131968375,
      "image": "",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) and Alliance Foundation Trials announced results from the Phase 3 PATINA trial demonstrating that the addition of Ibrance to current standard-of-care first-line maintenance therapy resulted in statistically significant and clinically meaningful improvement in progression-free survival, or PFS, by investigator assessment in patients with hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer. In the study, which is sponsored by AFT, medi",
      "url": "https://finnhub.io/api/news?id=6b3e844fca8c0fa45fef1bccbdb8f1ba8df0e9f4fa50e15d87d9cb49261d7208"
    }
  },
  {
    "ts": null,
    "headline": "SABCS: Pfizer’s IBRANCE combo improves PFS in breast cancer study",
    "summary": "The early results presented before the San Antonio Breast Cancer Symposium saw an increased rate of progression-free survival.",
    "url": "https://finnhub.io/api/news?id=0a2c0fa868d60f2c402c8ef5557653b72116b49a8e7b8f4afe575d766c162da5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734094539,
      "headline": "SABCS: Pfizer’s IBRANCE combo improves PFS in breast cancer study",
      "id": 131968377,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/22/2024/12/shutterstock_2006521388-7.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The early results presented before the San Antonio Breast Cancer Symposium saw an increased rate of progression-free survival.",
      "url": "https://finnhub.io/api/news?id=0a2c0fa868d60f2c402c8ef5557653b72116b49a8e7b8f4afe575d766c162da5"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: promising trial for Ibrance in breast cancer",
    "summary": "Pfizer announces that a Phase 3 trial demonstrated that the addition of Ibrance to standard maintenance therapy 'significantly' improved progression-free survival in patients with HR+/HER2+...",
    "url": "https://finnhub.io/api/news?id=cbf65e3855904536ed726a8d4ed0ac74edd36d0bf5942d0692fe215e44d4f1ff",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734082273,
      "headline": "Pfizer: promising trial for Ibrance in breast cancer",
      "id": 131966134,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer announces that a Phase 3 trial demonstrated that the addition of Ibrance to standard maintenance therapy 'significantly' improved progression-free survival in patients with HR+/HER2+...",
      "url": "https://finnhub.io/api/news?id=cbf65e3855904536ed726a8d4ed0ac74edd36d0bf5942d0692fe215e44d4f1ff"
    }
  },
  {
    "ts": null,
    "headline": "Will the ‘anti-woke’ movement derail DEI efforts in pharma?",
    "summary": "Amid the DEI backlash in corporate America, pharma leaders are quietly adjusting tactics.",
    "url": "https://finnhub.io/api/news?id=706473d031224e710d5ef15a513d42d3df3b501e7fcdcecbd8d7c697be1abac6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734076273,
      "headline": "Will the ‘anti-woke’ movement derail DEI efforts in pharma?",
      "id": 131968379,
      "image": "https://imgproxy.divecdn.com/SMxnrLn2Bjhr1-uoLiBZfnkaHUDXs2ovxVu_zu3RbI0/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTU4OTUyMTY4LmpwZw==.webp",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Amid the DEI backlash in corporate America, pharma leaders are quietly adjusting tactics.",
      "url": "https://finnhub.io/api/news?id=706473d031224e710d5ef15a513d42d3df3b501e7fcdcecbd8d7c697be1abac6"
    }
  }
]